Abstract
Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.
| Original language | English |
|---|---|
| Pages (from-to) | 77-84 |
| Number of pages | 8 |
| Journal | Practica Otologica |
| Volume | 93 |
| Issue number | 1 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Chronic otitis media
- Levofloxacin (LVFX)
- MRSA
ASJC Scopus subject areas
- Otorhinolaryngology
Cite this
High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media. / Nishizaki, Kazunori; Akagi, Hirofumi; Fukushima, Kunihiro; Masuda, Yu; Maeta, Manabu; Takeda, Yasushi; Ogawara, Toshiaki; Kariya, Shin; Akagi, Seiko; Teshima, Hiroyuki; Shirakami, Kaori.
In: Practica Otologica, Vol. 93, No. 1, 2000, p. 77-84.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - High-dose administration of levofloxacin (LVFX) in the treatment of acute exacerbation of chronic otitis media
AU - Nishizaki, Kazunori
AU - Akagi, Hirofumi
AU - Fukushima, Kunihiro
AU - Masuda, Yu
AU - Maeta, Manabu
AU - Takeda, Yasushi
AU - Ogawara, Toshiaki
AU - Kariya, Shin
AU - Akagi, Seiko
AU - Teshima, Hiroyuki
AU - Shirakami, Kaori
PY - 2000
Y1 - 2000
N2 - Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.
AB - Thirty-two adult cases of acute exacerbation of chronic otitis media (COM) were treated by high-dose (600 mg/day) oral administration of levofloxacin (LVFX). Clinically, 27 COM cases (84.4%) were effectively treated, and no apparent side effects were noted during this study protocol. Among 31 clinically isolated strains whose therapeutic outcomes were bacteriologically confirmed, 28(90%) strains were not detectable after high- dose LVFX treatment. Bacteriological therapeutic failures in the treatment were observed in three COM patients with MRSA and a patient with coagulase- negative staphylococci. High-dose administration of LVFX was effective in the treatment of acute exacerbation of COM except in cases that were caused by drug resistant staphylococci.
KW - Chronic otitis media
KW - Levofloxacin (LVFX)
KW - MRSA
UR - http://www.scopus.com/inward/record.url?scp=0033959488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033959488&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0033959488
VL - 93
SP - 77
EP - 84
JO - Practica Otologica
JF - Practica Otologica
SN - 0032-6313
IS - 1
ER -